From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Medical Countermeasures for Treatment of Radiation Injuries

by Global Biodefense Staff
June 22, 2012

The National Institute of Allergy and Infectious Diseases (NIAID) this week posted a funding opportunity seeking proposals for research focused on medical therapies and diagnostics to counter radiation injury.

The focus of the solicitation is to promote science leading towards treatments for mass casualty situations, with the ultimate goal of advancement of research on treatments of short- and long-term consequences of radiation exposure for civilian populations in the event of a nuclear incident, whether intentional or accidental.  Studies ranging from investigations into the mechanisms of action for a candidate medical countermeasure to advanced product development are requested.

Studies in animal models will be required to demonstrate efficacy of the medical countermeasure products.  Applicants are strongly encouraged to justify the selection of their animal model, and its relevance to expected human responses.  The program will support in vivo animal research to advance medical products already licensed (for other indications) or approaches in early developmental stages for any indication (including radiation).  All applicants must already have a lead medical countermeasure candidate.

Concern about the threat of nuclear or radiological attacks has grown in recent years due to the increased activity of global terrorist organizations and documented illicit trafficking of radioactive materials. Further, the effects of natural disasters on nuclear power facilities, such as the Fukushima plant in Japan, highlight the need to stockpile countermeasures to treat radiation injuries in the civilian population.

NIAID’s Radiation and Nuclear Countermeasures Program places an emphasis on translational research of treatments for radiation injury, which are effective when administered 24 hours or later after exposure from an accident or intentional attack. NIAID’s program is already yielding new candidate mitigators and therapeutic agents, which are moving toward product licensure by the U.S. Food and Drug Administration (FDA).  This funding opportunity adds to this effort.

NIAID intends to commit $4 million in FY 2013 to fund 6-8 awards under this opportunity. Full details are available in the NIH Grants Guide Solicitation Number: RFA-AI-12-023. The application deadline is October 18, 2012.

From Our Partners
Tags: Animal ModelsRequest for Proposals

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC